Zobrazeno 1 - 10
of 223
pro vyhledávání: '"Juliann Chmielecki"'
Autor:
Sebastijan Hobor, Maise Al Bakir, Crispin T. Hiley, Marcin Skrzypski, Alexander M. Frankell, Bjorn Bakker, Thomas B. K. Watkins, Aleksandra Markovets, Jonathan R. Dry, Andrew P. Brown, Jasper van der Aart, Hilda van den Bos, Diana Spierings, Dahmane Oukrif, Marco Novelli, Turja Chakrabarti, Adam H. Rabinowitz, Laila Ait Hassou, Saskia Litière, D. Lucas Kerr, Lisa Tan, Gavin Kelly, David A. Moore, Matthew J. Renshaw, Subramanian Venkatesan, William Hill, Ariana Huebner, Carlos Martínez-Ruiz, James R. M. Black, Wei Wu, Mihaela Angelova, Nicholas McGranahan, Julian Downward, Juliann Chmielecki, Carl Barrett, Kevin Litchfield, Su Kit Chew, Collin M. Blakely, Elza C. de Bruin, Floris Foijer, Karen H. Vousden, Trever G. Bivona, TRACERx consortium, Robert E. Hynds, Nnennaya Kanu, Simone Zaccaria, Eva Grönroos, Charles Swanton
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-21 (2024)
Abstract The phenomenon of mixed/heterogenous treatment responses to cancer therapies within an individual patient presents a challenging clinical scenario. Furthermore, the molecular basis of mixed intra-patient tumor responses remains unclear. Here
Externí odkaz:
https://doaj.org/article/a58c4b29e1d8491b8078212067633916
Autor:
Juliann Chmielecki, Jhanelle E. Gray, Ying Cheng, Yuichiro Ohe, Fumio Imamura, Byoung Chul Cho, Meng-Chih Lin, Margarita Majem, Riyaz Shah, Yuri Rukazenkov, Alexander Todd, Aleksandra Markovets, J. Carl Barrett, Ryan J. Hartmaier, Suresh S. Ramalingam
Publikováno v:
Nature Communications, Vol 14, Iss 1, Pp 1-9 (2023)
Abstract Osimertinib, an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), potently and selectively inhibits EGFR-TKI-sensitizing and EGFR T790M resistance mutations. In the Phase III FLAURA study (NCT02296125), first-line osimer
Externí odkaz:
https://doaj.org/article/44b83896764b4d85bc01ecb3c4630dd4
Autor:
Juliann Chmielecki, Tony Mok, Yi-Long Wu, Ji-Youn Han, Myung-Ju Ahn, Suresh S. Ramalingam, Thomas John, Isamu Okamoto, James Chih-Hsin Yang, Frances A. Shepherd, Krishna C. Bulusu, Gianluca Laus, Barbara Collins, J. Carl Barrett, Ryan J. Hartmaier, Vassiliki Papadimitrakopoulou
Publikováno v:
Nature Communications, Vol 14, Iss 1, Pp 1-8 (2023)
In the phase III AURA3 study (NCT02151981), the third-generation epidermal growth factor receptor tyrosine kinase inhibitor osimertinib prolonged progression-free survival versus platinum-doublet chemotherapy in patients with EGFR T790M advanced NSCL
Externí odkaz:
https://doaj.org/article/97023c9e42e0450eab3688b9d4689761
Autor:
Juliann Chmielecki, Jhanelle E. Gray, Ying Cheng, Yuichiro Ohe, Fumio Imamura, Byoung Chul Cho, Meng-Chih Lin, Margarita Majem, Riyaz Shah, Yuri Rukazenkov, Alexander Todd, Aleksandra Markovets, J. Carl Barrett, Ryan J. Hartmaier, Suresh S. Ramalingam
Publikováno v:
Nature Communications, Vol 14, Iss 1, Pp 1-2 (2023)
Externí odkaz:
https://doaj.org/article/9ac77df433144c60bb72e35db443b3df
Autor:
Tereza Vaclova, Ursula Grazini, Lewis Ward, Daniel O’Neill, Aleksandra Markovets, Xiangning Huang, Juliann Chmielecki, Ryan Hartmaier, Kenneth S. Thress, Paul D. Smith, J. Carl Barrett, Julian Downward, Elza C. de Bruin
Publikováno v:
Nature Communications, Vol 12, Iss 1, Pp 1-11 (2021)
A recent clinical trial shows that a proportion of lung cancer patients carrying the EGFR T790M mutation develop resistance to osimertinib. In this study, the authors show that T790M subclonality is associated with worse clinical outcome likely throu
Externí odkaz:
https://doaj.org/article/481ad63fcd374f3eb7bb421d24c7891e
Autor:
Zachary R. Chalmers, Caitlin F. Connelly, David Fabrizio, Laurie Gay, Siraj M. Ali, Riley Ennis, Alexa Schrock, Brittany Campbell, Adam Shlien, Juliann Chmielecki, Franklin Huang, Yuting He, James Sun, Uri Tabori, Mark Kennedy, Daniel S. Lieber, Steven Roels, Jared White, Geoffrey A. Otto, Jeffrey S. Ross, Levi Garraway, Vincent A. Miller, Phillip J. Stephens, Garrett M. Frampton
Publikováno v:
Genome Medicine, Vol 9, Iss 1, Pp 1-14 (2017)
Abstract Background High tumor mutational burden (TMB) is an emerging biomarker of sensitivity to immune checkpoint inhibitors and has been shown to be more significantly associated with response to PD-1 and PD-L1 blockade immunotherapy than PD-1 or
Externí odkaz:
https://doaj.org/article/fb907a4b3aaf43769173e9ac0018e2eb
Autor:
Leonard D. Goldstein, James Lee, Florian Gnad, Christiaan Klijn, Annalisa Schaub, Jens Reeder, Anneleen Daemen, Corey E. Bakalarski, Thomas Holcomb, David S. Shames, Ryan J. Hartmaier, Juliann Chmielecki, Somasekar Seshagiri, Robert Gentleman, David Stokoe
Publikováno v:
Cell Reports, Vol 16, Iss 10, Pp 2605-2617 (2016)
The Nrf2 pathway is frequently activated in human cancers through mutations in Nrf2 or its negative regulator KEAP1. Using a cell-line-derived gene signature for Nrf2 pathway activation, we found that some tumors show high Nrf2 activity in the absenc
Externí odkaz:
https://doaj.org/article/e594afbe1e7541f5bfa7c4dffdee5106
Autor:
Lee A Albacker, Jeremy Wu, Peter Smith, Markus Warmuth, Philip J Stephens, Ping Zhu, Lihua Yu, Juliann Chmielecki
Publikováno v:
PLoS ONE, Vol 12, Iss 11, p e0176181 (2017)
Immune evasion is a well-recognized hallmark of cancer and recent studies with immunotherapy agents have suggested that tumors with increased numbers of neoantigens elicit greater immune responses. We hypothesized that the immune system presents a co
Externí odkaz:
https://doaj.org/article/d48f7087d6474058b507fa193b52f668
Autor:
Angela N Brooks, Peter S Choi, Luc de Waal, Tanaz Sharifnia, Marcin Imielinski, Gordon Saksena, Chandra Sekhar Pedamallu, Andrey Sivachenko, Mara Rosenberg, Juliann Chmielecki, Michael S Lawrence, David S DeLuca, Gad Getz, Matthew Meyerson
Publikováno v:
PLoS ONE, Vol 9, Iss 1, p e87361 (2014)
Although recurrent somatic mutations in the splicing factor U2AF1 (also known as U2AF35) have been identified in multiple cancer types, the effects of these mutations on the cancer transcriptome have yet to be fully elucidated. Here, we identified sp
Externí odkaz:
https://doaj.org/article/0ed24c85ef0e4b54b65f5d4ffd3aec84
Autor:
Yixuan Gong, Romel Somwar, Katerina Politi, Marissa Balak, Juliann Chmielecki, Xuejun Jiang, William Pao
Publikováno v:
PLoS Medicine, Vol 4, Iss 10, p e294 (2007)
Mutations in the epidermal growth factor receptor (EGFR) gene are associated with increased sensitivity of lung cancers to kinase inhibitors like erlotinib. Mechanisms of cell death that occur after kinase inhibition in these oncogene-dependent tumor
Externí odkaz:
https://doaj.org/article/e1d737c242f048f6b1a3dab9c2f98547